NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its second-quarter revenues grew 12 percent year over year, driven by a 24 percent spike in its assay revenue.

The Austin, Texas-based molecular diagnostics firm reported total revenues of $54.3 million for the three months ended June 30, compared to $48.3 million for the second quarter of 2012. It inched past analysts' consensus estimate for revenues of $54.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.